Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors

Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen I, Scheel AH, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, Koenig K, Schildhaus HU, Fassunke J, Ihle MA, Pasternacko H, Heydt C, Becker C, Altmueller J, Ji H, Mueller C, Florin A, Heuckmann JM, Nuernberg P, Ansen S, Heukamp LC, Berg J, Pao W, Peifer M, Buettner R, Wolfe J, Thomas RK, Sos ML (2016)


Publication Type: Journal article

Publication year: 2016

Journal

Book Volume: 22

Pages Range: 4837-4847

Journal Issue: 19

DOI: 10.1158/1078-0432.CCR-15-1915

Abstract

Purpose: To identify novel mechanisms of resistance to thirdgeneration EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686). Experimental Design: We analyzed tumor biopsies from seven patients obtained before, during, and/or after treatment with AZD9291 or rociletinib (CO-1686). Targeted sequencing and FISH analyses were performed, and the relevance of candidate genes was functionally assessed in in vitro models. Results: We found recurrent amplification of either MET or ERBB2 in tumors that were resistant or developed resistance to third-generation EGFR inhibitors and show that ERBB2 and MET activation can confer resistance to these compounds. Furthermore, we identified a KRASG12S mutation in a patient with acquired resistance to AZD9291 as a potential driver of acquired resistance. Finally, we show that dual inhibition of EGFR/MEK might be a viable strategy to overcome resistance in EGFR-mutant cells expressing mutant KRAS. Conclusions: Our data suggest that heterogeneous mechanisms of resistance can drive primary and acquired resistance to third-generation EGFR inhibitors and provide a rationale for potential combination strategies. Clin Cancer Res; 22(19); 4837-47.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Ortiz-Cuaran, S., Scheffler, M., Plenker, D., Dahmen, I., Scheel, A.H., Fernandez-Cuesta, L.,... Sos, M.L. (2016). Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clinical Cancer Research, 22(19), 4837-4847. https://doi.org/10.1158/1078-0432.CCR-15-1915

MLA:

Ortiz-Cuaran, Sandra, et al. "Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors." Clinical Cancer Research 22.19 (2016): 4837-4847.

BibTeX: Download